Bradenton Research Center | Bradenton, FL
Status and phase
Conditions
Treatments
Study type
Funder types
Identifiers
About
The primary objective is to evaluate the safety and tolerability of aducanumab over 100 weeks of treatment after a wash-out period imposed by discontinuation of feeder studies in participants who had previously received aducanumab (i.e. previously treated participants) or who had previously received placebo (i.e. treatment-naïve participants).
Enrollment
Sex
Ages
Volunteers
Inclusion and exclusion criteria
Key Inclusion Criteria:
Core Treatment Period:
LTE Treatment Period:
Key Exclusion Criteria:
Core Treatment Period:
LTE Treatment Period:
Note- Other protocol defined Inclusion/Exclusion criteria may apply.
Primary purpose
Allocation
Interventional model
Masking
1,696 participants in 1 patient group
Loading...
Data sourced from clinicaltrials.gov
Clinical trials
Research sites
Resources
Legal